BRIEF published on 05/11/2026 at 08:05, 1 month 13 days ago Pentixapharm Submits IND to FDA for Phase 3 PANDA Study Pentixapharm Precision Diagnostics FDA IND Submission Phase 3 PANDA Cardiovascular Imaging
PRESS RELEASE published on 05/11/2026 at 08:00, 1 month 13 days ago Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism Pentixapharm IND Submission Phase 3 PANDA Study CXCR4-targeted Cardiovascular Diagnostic
BRIEF published on 05/07/2026 at 08:05, 1 month 17 days ago Point sur le développement financier et clinique de Pentixapharm au premier trimestre 2026 Résultats Financiers Développement Clinique Gestion Des Coûts Produits Radiopharmaceutiques Commentaires Réglementaires
BRIEF published on 05/07/2026 at 08:05, 1 month 17 days ago Pentixapharm Q1 2026 Financial and Clinical Development Update Financial Results Clinical Development Radiopharmaceuticals Cost Management Regulatory Feedback
PRESS RELEASE published on 05/07/2026 at 08:00, 1 month 17 days ago Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum Pentixapharm Holding AG reports Q1 2026 financial results, highlights progress in clinical and regulatory activities, and provides full-year financial guidance Financial Results Regulatory Pentixapharm Q1 2026 Clinical
BRIEF published on 03/31/2026 at 08:05, 2 months 24 days ago Pentixapharm Holding AG nomme Erik Merten au conseil d'administration Conseil D'administration Produits Radiopharmaceutiques Pentixapharm Erik Merten Programme PANDA
BRIEF published on 03/31/2026 at 08:05, 2 months 24 days ago Pentixapharm Holding AG Appoints Erik Merten to Executive Board Executive Board Radiopharmaceuticals Pentixapharm Erik Merten PANDA Program
PRESS RELEASE published on 03/31/2026 at 08:00, 2 months 24 days ago Pentixapharm Holding AG Appoints Erik Merten to the Executive Board Pentixapharm Holding AG appoints Erik Merten as Chief Technology Officer (CTO) to enhance radiopharmaceutical development and manufacturing capabilities, supporting Phase 3 PANDA program and future commercialization Executive Board Radiopharmaceuticals Pentixapharm Holding AG Erik Merten Phase 3 PANDA Program
BRIEF published on 03/19/2026 at 10:19, 3 months 5 days ago Pentixapharm Holding AG to Reveal 2025 Financial Results Conference Call Clinical Trials Pentixapharm Radiotherapeutics 2025 Financial Results
BRIEF published on 03/19/2026 at 10:19, 3 months 5 days ago Pentixapharm Holding AG publiera ses résultats financiers pour 2025 Conférence Téléphonique Essais Cliniques Pentixapharm Radiothérapie Résultats Financiers De 2025
Published on 06/24/2026 at 23:05, 25 minutes ago Polaris Modifies Quorum Requirement for Upcoming AGM
Published on 06/24/2026 at 22:15, 1 hour 15 minutes ago Organto Foods Announces Annual General Meeting Results
Published on 06/24/2026 at 21:20, 2 hours 10 minutes ago Taranis to Explore New Properties East of Thor Mineral Resource
Published on 06/24/2026 at 20:10, 3 hours 20 minutes ago Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited
Published on 06/24/2026 at 20:54, 2 hours 35 minutes ago EQS-Adhoc: Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/24/2026 at 18:25, 5 hours 4 minutes ago Huawei Helps Global Carriers Monetize Tokens with Service-Network-Compute Integration
Published on 06/24/2026 at 18:25, 5 hours 5 minutes ago Annual General Meeting of Highlight Event and Entertainment AG
Published on 06/24/2026 at 19:00, 4 hours 30 minutes ago ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 5 hours 30 minutes ago KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 5 hours 45 minutes ago Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno
